Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Spasmodic dysphonia in an adolescent patient with an autoimmune neurologic disorder.

Boseley ME, Gherson S, Hartnick CJ.

Am J Otolaryngol. 2007 Mar-Apr;28(2):140-2.

PMID:
17362824
2.
4.

Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.

Casserly P, Timon C.

J Laryngol Otol. 2008 Jan;122(1):52-6. Epub 2007 May 1.

PMID:
17470307
5.

Botox treatment in adductor spasmodic dysphonia: a meta-analysis.

Boutsen F, Cannito MP, Taylor M, Bender B.

J Speech Lang Hear Res. 2002 Jun;45(3):469-81.

PMID:
12069000
6.

Supraglottal injection of botulinum toxin type A in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction.

Schönweiler R, Wohlfarth K, Dengler R, Ptok M.

Laryngoscope. 1998 Jan;108(1 Pt 1):55-63.

PMID:
9432068
7.

Annotation: PANDAS: a model for human autoimmune disease.

Swedo SE, Grant PJ.

J Child Psychol Psychiatry. 2005 Mar;46(3):227-34.

PMID:
15755299
8.

Does group A beta-hemolytic streptococcal infection increase risk for behavioral and neuropsychiatric symptoms in children?

Perrin EM, Murphy ML, Casey JR, Pichichero ME, Runyan DK, Miller WC, Snider LA, Swedo SE.

Arch Pediatr Adolesc Med. 2004 Sep;158(9):848-56.

PMID:
15351749
9.

Clinical application of botulinum toxin in otolaryngology, head and neck practice (brief review).

Yin S, Stucker FJ, Nathan CO.

J La State Med Soc. 2001 Feb;153(2):92-7. Review.

PMID:
11261363
10.
11.

Prospective longitudinal study of children with tic disorders and/or obsessive-compulsive disorder: relationship of symptom exacerbations to newly acquired streptococcal infections.

Luo F, Leckman JF, Katsovich L, Findley D, Grantz H, Tucker DM, Lombroso PJ, King RA, Bessen DE.

Pediatrics. 2004 Jun;113(6):e578-85.

PMID:
15173540
12.

[PANDAS--Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection: is it a specific clinical disorder?].

Singer HS.

Rev Bras Psiquiatr. 2004 Dec;26(4):220-1. Epub 2005 Feb 23. Portuguese. No abstract available.

13.

Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.

Sulica L, Blitzer A, Brin MF, Stewart CF.

Ann Otol Rhinol Laryngol. 2003 Jun;112(6):499-505.

PMID:
12834116
14.

The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia.

Epstein R, Stygall J, Newman S.

Disabil Rehabil. 1997 Jan;19(1):20-5.

PMID:
9021281
15.
17.

Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia.

Anari S, Carding PN, Hawthorne MR, Deakin J, Drinnan MJ.

Laryngoscope. 2007 Oct;117(10):1888-92.

PMID:
17690610
18.

[Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). A report of two cases].

Bryńska A, Wolańczyk T.

Psychiatr Pol. 2004 Jan-Feb;38(1):105-23. Review. Polish.

PMID:
15042736
19.

Post-streptococcal autoimmune disorders of the central nervous system.

Snider LA, Swedo SE.

Curr Opin Neurol. 2003 Jun;16(3):359-65. Review.

PMID:
12858074
20.

Efficacy of a portable, audible-only electromyography device in the treatment of spasmodic dysphonia.

Jeffcoat BT, Schweinfurth JM.

Laryngoscope. 2008 May;118(5):942-3. doi: 10.1097/MLG.0b013e3181639b7e. No abstract available.

PMID:
18197130

Supplemental Content

Support Center